Baxter India Pvt. Ltd. (MD Anish Bafna, www.baxter.in) a subsidiary of global healthcare company, Baxter International Inc. (NYSE:BAX), announced the launch of Plasma-Lyte A (pH 7.4), a physiologically balanced crystalloid solution, having similar electrolyte constitution to that of blood plasma. Plasma-Lyte A advances the clinical practice of IV Therapy in India for critically ill patients especially in the ICU where the selection of the right IV fluids can help avoid complications, morbidities and mortality1, 2.
Plasma-Lyte addresses these clinically unmet needs and issues, bringing a balanced solution with sodium, potassium, magnesium and chloride levels similar to plasma7. The absence of calcium in the solution means, it can be administered before, during or after blood transfusion 6. Plasma-Lyte does not exacerbate metabolic acidosis, nor does it complicate the evaluation of metabolic acidosis 13. Plasma-Lyte reduces the risk of hyperchloremic acidosis compared to those receiving normal saline and does not adversely affect acid base status 1,2,3,4,5,8
Currently administered IV fluid therapies in India include Colloids (6% hydroxyethyl starch, albumin) and Crystalloids (Ringers Lactate, Ringer’s Acetate, Normal Saline). Fluid resuscitation with normal saline encompasses high levels of sodium and chloride and can result in detrimental clinical outcomes by causing hyperchloremic metabolic acidosis, reduced renal perfusion, and immune dysfunction, especially in major surgery1,5 .Some other balanced crystalloid solutions like Lactated Ringer’s solution cannot be co-administered with citrate preserved blood, as the calcium affects the anticoagulant properties of citrate 6. Large volume infusion of Ringer’s lactate can also lead to complications of hyponatremia and acidosis as seen during major spine surgery9.
Hydroxyethyl starch (HES), a commonly used colloid in fluid therapy in critically ill patients, is associated with serious safety issues leading to increased need for renal replacement therapy, increased mortality and higher risk of kidney dysfunction 10, 11.
Dr. Ashok Moharana, Director, Medical Affairs, Emerging Asia says, “Studies show that 17% of post-operative patients develop morbidity directly related to fluid prescription and errors in fluid prescription common in hospital practice, are a major safety concern3,4. Plasma-Lyte A is a physiologically balanced electrolyte solution that addresses the unmet medical need of having a fluid that has similar electrolyte constitution to that of plasma7. This will help to optimize standards of care in clinical practice of IV fluids therapy in India, thereby improving clinical outcomes in patients care.
Plasma-Lyte is currently available in 38 countries.
About Baxter
Baxter India Private Limited is a wholly owned subsidiary of Baxter International Inc. (NYSE:BAX), which, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
References
1. Shaw AD et al. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte. Ann Surg. 2012 May;255(5):821-9.-7.
2. Hadimioglu N et al. The effect of different crystalloid solutions on acid-base balance and early kidney function after kidney transplantation. Anesth Analg.2008; 107(1):264-9
3. Walsh S. R et al. Intravenous fluid-associated morbidity in postoperative patients. Ann R Coll Surg Engl. 2005 March; 87(2): 126–130.
4. Shaifee et al. How to select optimal maintenance intravenous fluid therapy. Q J Med. 2003;96:601–610
5 Chowdhury A et al. A randomized, controlled, double-blind crossover study on the effects of 2-l infusions of 0.9% Saline and Plasma-Lyte 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg. 2012 Jul; 256(1) :18-24.
6 Guidelines for the Administration of Blood Components. Australia & New Zealand Society of Blood Transfusion Inc./Royal College of Nursing Australia 2004; 1st Edition: p11.
7 Rizoli S. PlasmaLyte. J Trauma. 2011 May;70(5 Suppl):S17-8.
8 McFarlane C et al. A comparison of Plasmalyte 148 and 0.9% saline for intra-operative fluid replacement. Anaesthesia 1994;49:779–81
9 Takil A et al. Early postoperative respiratory acidosis after large intravascular volume infusion of lactated ringer's solution during major spine surgery. Anesthesia & Analgesia. 2002;95:294–298.
10 Myburgh JA et al. Hydroxyethyl starch or Saline for fluid resuscitation in Intensive care N Eng J Med 2012;367:1901−11.
11 Perner A et al. Hydroxyethyl Starch 130/0.4 versus Ringer’s Acetate in Severe Sepsis N Engl J Med. 2012 ;367(2):124-34
12 Walker HK et al. 3rd ed. Boston: Butterworths; 1990.
13 Yunos NM et al. Biochemical effects of restricting Chloride rich fluids in Intensive care Crit Care Med 2011;39:2419–24.
Plasma-Lyte addresses these clinically unmet needs and issues, bringing a balanced solution with sodium, potassium, magnesium and chloride levels similar to plasma7. The absence of calcium in the solution means, it can be administered before, during or after blood transfusion 6. Plasma-Lyte does not exacerbate metabolic acidosis, nor does it complicate the evaluation of metabolic acidosis 13. Plasma-Lyte reduces the risk of hyperchloremic acidosis compared to those receiving normal saline and does not adversely affect acid base status 1,2,3,4,5,8
Currently administered IV fluid therapies in India include Colloids (6% hydroxyethyl starch, albumin) and Crystalloids (Ringers Lactate, Ringer’s Acetate, Normal Saline). Fluid resuscitation with normal saline encompasses high levels of sodium and chloride and can result in detrimental clinical outcomes by causing hyperchloremic metabolic acidosis, reduced renal perfusion, and immune dysfunction, especially in major surgery1,5 .Some other balanced crystalloid solutions like Lactated Ringer’s solution cannot be co-administered with citrate preserved blood, as the calcium affects the anticoagulant properties of citrate 6. Large volume infusion of Ringer’s lactate can also lead to complications of hyponatremia and acidosis as seen during major spine surgery9.
Hydroxyethyl starch (HES), a commonly used colloid in fluid therapy in critically ill patients, is associated with serious safety issues leading to increased need for renal replacement therapy, increased mortality and higher risk of kidney dysfunction 10, 11.
Dr. Ashok Moharana, Director, Medical Affairs, Emerging Asia says, “Studies show that 17% of post-operative patients develop morbidity directly related to fluid prescription and errors in fluid prescription common in hospital practice, are a major safety concern3,4. Plasma-Lyte A is a physiologically balanced electrolyte solution that addresses the unmet medical need of having a fluid that has similar electrolyte constitution to that of plasma7. This will help to optimize standards of care in clinical practice of IV fluids therapy in India, thereby improving clinical outcomes in patients care.
Plasma-Lyte is currently available in 38 countries.
About Baxter
Baxter India Private Limited is a wholly owned subsidiary of Baxter International Inc. (NYSE:BAX), which, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.
References
1. Shaw AD et al. Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte. Ann Surg. 2012 May;255(5):821-9.-7.
2. Hadimioglu N et al. The effect of different crystalloid solutions on acid-base balance and early kidney function after kidney transplantation. Anesth Analg.2008; 107(1):264-9
3. Walsh S. R et al. Intravenous fluid-associated morbidity in postoperative patients. Ann R Coll Surg Engl. 2005 March; 87(2): 126–130.
4. Shaifee et al. How to select optimal maintenance intravenous fluid therapy. Q J Med. 2003;96:601–610
5 Chowdhury A et al. A randomized, controlled, double-blind crossover study on the effects of 2-l infusions of 0.9% Saline and Plasma-Lyte 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg. 2012 Jul; 256(1) :18-24.
6 Guidelines for the Administration of Blood Components. Australia & New Zealand Society of Blood Transfusion Inc./Royal College of Nursing Australia 2004; 1st Edition: p11.
7 Rizoli S. PlasmaLyte. J Trauma. 2011 May;70(5 Suppl):S17-8.
8 McFarlane C et al. A comparison of Plasmalyte 148 and 0.9% saline for intra-operative fluid replacement. Anaesthesia 1994;49:779–81
9 Takil A et al. Early postoperative respiratory acidosis after large intravascular volume infusion of lactated ringer's solution during major spine surgery. Anesthesia & Analgesia. 2002;95:294–298.
10 Myburgh JA et al. Hydroxyethyl starch or Saline for fluid resuscitation in Intensive care N Eng J Med 2012;367:1901−11.
11 Perner A et al. Hydroxyethyl Starch 130/0.4 versus Ringer’s Acetate in Severe Sepsis N Engl J Med. 2012 ;367(2):124-34
12 Walker HK et al. 3rd ed. Boston: Butterworths; 1990.
13 Yunos NM et al. Biochemical effects of restricting Chloride rich fluids in Intensive care Crit Care Med 2011;39:2419–24.
